ArticlePLoS neglected tropical diseases2026
Development of a multiplex quantitative real-time PCR (qPCR) assay for simultaneous detection of Schistosoma haematobium and high-risk human papillomaviruses.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemale genital schistosomiasis (FGS) and high-risk human papillomavirus (hr-HPV) infections frequently co-occur in sub-Saharan Africa and may jointly contribute to cervical carcinogenesis. However, no existing molecular platform enables simultaneous detection of Schistosoma haematobium and hr-HPV from a single cervical specimen.
methodsA multiplex quantitative real-time PCR (qPCR) assay targeting the S. haematobium Dra1 repeat and seven hr-HPV genotypes (16, 18, 31, 33, 45, 52, 58) was developed and validated. Analytical performance was assessed using HPV reference plasmids from the International HPV Reference Centre and biobanked S. haematobium DNA from the Centre for Research in Applied Biology (CeRAB), Ghana. Clinical performance was evaluated using 217 archived cervical swabs from high-risk women enrolled in the CERVIVAL project in rural Ghana.
resultsThe assay showed a limit of detection of 10 copies/µL for all targets, with no cross-reactivity to non-target HPV genotypes, common uropathogenic bacteria, or Schistosoma mansoni. In reference panels, positive and negative agreement were 98.2% and 100% for S. haematobium and 100% for both sensitivity and specificity across all hr-HPV genotypes. In the 217 high-risk cervical samples, S. haematobium DNA was detected in 56.7% (123/217). HPV58 (19.8%), HPV16 (14.7%), and HPV52 (12.4%) were the most frequent genotypes. Concordance with visual inspection/microscopy for FGS was 93.6% (κ = 0.87), and concordance with a molecular HPV test (ScreenFire HPV) ranged from 90.3% to 99.5% (κ = 0.80-0.95) across HPV channels. The assay identified 11 additional S. haematobium-positive samples that were negative by visual inspection/microscopy.
conclusionsThe multiplex qPCR assay provides a highly sensitive and practical tool for integrated detection of S. haematobium and hr-HPV from a single cervical sample. Its compatibility with standard qPCR platforms and strong agreement with established diagnostic methods support its potential use in FGS and cervical cancer screening programmes in resource-limited, co-endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.